These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19089462)

  • 1. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
    Weide R; Koppler H; Antras L; Smith M; Chang MP; Green J; Wintfeld N; Neary MP; Duh MS
    J Cancer Res Ther; 2010; 6(1):31-5. PubMed ID: 20479544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
    Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
    Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
    Cha YJ; Lee YJ
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
    Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
    J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
    Shah SR; Jean GW; Keisner SV; Ussery SM; Dowell JE
    Support Care Cancer; 2012 Jan; 20(1):87-93. PubMed ID: 21197550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.
    Berruti A; Cook R; Saad F; Buttigliero C; Lipton A; Tampellini M; Lee KA; Coleman RE; Smith MR
    Oncologist; 2012; 17(5):645-52. PubMed ID: 22523198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
    Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
    Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
    Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
    J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.
    McDermott RS; Kloth DD; Wang H; Hudes GR; Langer CJ
    J Support Oncol; 2006; 4(10):524-9. PubMed ID: 17136870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.